步长制药(603858) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,784,946,981.48, representing a 5.47% increase compared to ¥2,640,556,945.44 in the same period last year[3]. - Net profit attributable to shareholders increased by 169.49% to ¥307,261,088.17 from ¥114,015,551.69 year-on-year[3]. - Net profit for Q1 2025 was ¥289,890,204.09, significantly up from ¥87,698,871.86 in Q1 2024, representing a growth of 230.5%[16]. - Basic and diluted earnings per share rose by 180.10% to ¥0.2899 from ¥0.1035 in the same period last year[3]. - Earnings per share for Q1 2025 was ¥0.2899, compared to ¥0.1035 in Q1 2024, reflecting a substantial increase[16]. Cash Flow - The net cash flow from operating activities surged by 814.82% to ¥678,016,314.81, up from ¥74,114,961.92 in the previous year[3]. - Cash flow from operating activities for Q1 2025 was ¥678,016,314.81, a significant increase from ¥74,114,961.92 in Q1 2024, representing a growth of approximately 815.5%[20]. - Total cash inflow from operating activities in Q1 2025 reached ¥2,992,606,467.80, compared to ¥2,749,269,900.40 in Q1 2024, indicating an increase of about 8.8%[20]. - The total cash inflow from operating activities was primarily driven by an increase in cash received from sales, which amounted to ¥2,929,463,148.12 in Q1 2025, compared to ¥2,649,327,706.77 in Q1 2024[20]. - The company reported a decrease in cash paid for goods and services, which was ¥526,854,643.76 in Q1 2025, down from ¥636,791,962.37 in Q1 2024, indicating a reduction of approximately 17.3%[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥19,836,965,205.27, a 2.63% increase from ¥19,328,509,108.36 at the end of the previous year[3]. - Total current assets increased to ¥8,090,878,234.09 as of March 31, 2025, up from ¥7,537,198,596.50 at the end of 2024[11]. - Total liabilities rose to ¥9,786,024,120.20 as of March 31, 2025, compared to ¥9,520,425,198.24 at the end of 2024[12]. - The company reported a total asset value of ¥19,836,965,205.27 as of March 31, 2025, an increase from ¥19,328,509,108.36 at the end of 2024[12]. - The company’s total equity increased to ¥10,050,941,085.07 as of March 31, 2025, up from ¥9,808,083,910.12 at the end of 2024[12]. Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.53% to ¥10,475,032,314.12 from ¥10,216,464,921.09[3]. - The weighted average return on equity increased by 1.99 percentage points to 2.97%[3]. Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥7,672,820.13 for the period[5]. Strategic Developments - The increase in net profit was primarily driven by higher sales volume and changes in product sales structure, along with the acquisition of Tonghua Guhong Pharmaceutical Co., Ltd.[6]. - The company has not disclosed any new product or technology developments, market expansion, or merger and acquisition strategies in this report[10]. Cash Flow from Investing and Financing Activities - Cash outflow from investing activities in Q1 2025 was ¥339,677,008.39, a substantial rise from ¥87,326,830.66 in Q1 2024, reflecting an increase of approximately 288.5%[20]. - Net cash flow from investing activities for Q1 2025 was -¥336,787,235.62, worsening from -¥86,404,964.15 in Q1 2024[20]. - Cash inflow from financing activities in Q1 2025 totaled ¥683,395,102.72, down from ¥950,358,691.77 in Q1 2024, a decrease of about 28.1%[20]. - Net cash flow from financing activities for Q1 2025 was ¥272,065,937.17, compared to ¥332,495,910.56 in Q1 2024, showing a decline of approximately 18.2%[20]. Accounting Standards - The company did not apply new accounting standards for the first time in 2025, as stated in the announcement[21].